Galapagos NV (NASDAQ:GLPG)‘s stock had its “buy” rating reissued by equities research analysts at Cowen and Company in a report released on Thursday.

GLPG has been the topic of several other research reports. Janney Montgomery Scott cut shares of Galapagos NV from a “buy” rating to a “sell” rating in a research note on Monday, April 24th. BidaskClub cut shares of Galapagos NV from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Nomura lowered their target price on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating on the stock in a research note on Thursday, June 22nd. Stifel Nicolaus lifted their target price on shares of Galapagos NV from $65.00 to $83.00 and gave the stock a “hold” rating in a research note on Monday, May 1st. Finally, Zacks Investment Research cut shares of Galapagos NV from a “buy” rating to a “hold” rating in a research note on Monday, April 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $93.33.

Galapagos NV (NASDAQ:GLPG) traded up 11.22% during midday trading on Thursday, reaching $81.38. 2,768,165 shares of the company were exchanged. Galapagos NV has a 52 week low of $52.50 and a 52 week high of $94.88. The firm’s 50 day moving average price is $77.53 and its 200-day moving average price is $79.01. The stock’s market capitalization is $4.14 billion.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/cowen-and-company-reiterates-buy-rating-for-galapagos-nv-glpg/1469036.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC purchased a new position in shares of Galapagos NV during the first quarter valued at $161,000. Acadian Asset Management LLC purchased a new position in shares of Galapagos NV during the second quarter valued at $166,000. Bank of Montreal Can boosted its position in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares during the last quarter. Pacad Investment Ltd. purchased a new position in shares of Galapagos NV during the second quarter valued at $168,000. Finally, Cim Investment Mangement Inc. purchased a new position in shares of Galapagos NV during the first quarter valued at $203,000. 19.99% of the stock is currently owned by hedge funds and other institutional investors.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.